Abstract
Minimal residual disease (MRD) evaluation has a substantial impact in several hematological neoplasms, particularly in those in which effective treatments ensure the achievement of profound reductions of tumor burden. Given the impressive progress of multiple myeloma (MM) treatment, there is little surprise in observing an increased interest in the use of MRD evaluation tools for a better monitoring of treatment efficacy, currently in the context of clinical trials but, potentially, also in clinical practice. The aim of the present chapter is to provide an updated overview of MRD approaches in MM, including flow cytometry and molecular and imaging techniques. Apart from technical and methodological considerations, special attention has been devoted to a clinical-wise interpretation of currently available MRD results and to applications that might become available in the near future.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Abola MV, Prasad V, Jena AB (2014) Association between treatment toxicity and outcomes in oncology clinical trials. Ann Oncol 25(11):2284–2289. https://doi.org/10.1093/annonc/mdu444
Almeida J, Orfao A, Ocqueteau M, Mateo G, Corral M, Caballero MD et al (1999) High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma. Br J Haematol 107(1):121–131. http://www.ncbi.nlm.nih.gov/pubmed/10520032
Barlogie B, Anaissie E, Haessler J et al (2008) Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma. Cancer 113:355–359
Bartel TB, Haessler J, Brown TLY, Shaughnessy JD, van Rhee F, Anaissie E et al (2009) F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood 114(10):2068–2076. http://www.bloodjournal.org/cgi/doi/10.1182/blood-2009-03-213280
Bladé J, de Larrea CF, Rosiñol L (2012) Extramedullary involvement in multiple myeloma. Haematologica 97(11):1618–1619. http://www.haematologica.org/cgi/doi/10.3324/haematol.2012.078519
Böttcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch RM, Fingerle-Rowson G et al (2012) Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 30(9):980–988. http://ascopubs.org/doi/10.1200/JCO.2011.36.9348
Brüggemann M, Schrauder A, Raff T, Pfeifer H, Dworzak M, Ottmann OG, Asnafi V, Baruchel A, Bassan R, Benoit Y, Biondi A, Cavé H, Dombret H, Fielding AK, Foà R, Gökbuget N, Goldstone AH, Goulden N, Henze G, Hoelzer D, Janka-Schaub GE, Macintyre EA, Pieters R, Rambaldi A, Ribera JM, Schmiegelow K, Spinelli O, Stary J, von Stackelberg A, Kneba M, Schrappe M, van Dongen JJ, European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL).; International Berlin-Frankfurt-Münster Study Group (I-BFM-SG) (2010) Standardized MRD quantification in European ALL trials: proceedings of the second international symposium on MRD assessment in Kiel, Germany, 18–20 September 2008. Leukemia 24(3):521–535. https://doi.org/10.1038/leu.2009.268
Caers J, Withofs N, Hillengass J, Simoni P, Zamagni E, Hustinx R et al (2014) The role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow up of multiple myeloma. Haematologica 99(4):629–637. http://www.haematologica.org/cgi/doi/10.3324/haematol.2013.091918
Corradini P, Ladetto M, Astolfi M, Voena C, Tarella C, Bacigalupo A, Pileri A (1996) Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle-cell lymphoma. Br J Haematol 94(2):376–378
Dahl IMS, Rasmussen T, Kauric G, Husebekk A (2002) Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma. Br J Haematol 116(2):273–277. http://www.ncbi.nlm.nih.gov/pubmed/11841427
Davies FE, Forsyth PD, Rawstron AC, Owen RG, Pratt G, Evans PA et al (2001) The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma. Br J Haematol 112(3):814–819. http://www.ncbi.nlm.nih.gov/pubmed/11260088
de Larrea CF, Cibeira MT, Elena M, Arostegui JI, Rosiñol L, Rovira M et al (2009) Abnormal serum free light chain ratio in patients with multiple myeloma in complete remission has strong association with the presence of oligoclonal bands: implications for stringent complete remission definition. Blood 114(24):4954–4956. http://www.bloodjournal.org/cgi/doi/10.1182/blood-2009-06-224832
Derlin T, Weber C, Habermann CR, Herrmann J, Wisotzki C, Ayuk F et al (2012) 18F-FDG PET/CT for detection and localization of residual or recurrent disease in patients with multiple myeloma after stem cell transplantation. Eur J Nucl Med Mol Imaging 39(3):493–500. http://link.springer.com/10.1007/s00259-011-1993-8
Derlin T, Peldschus K, Münster S, Bannas P, Herrmann J, Stübig T et al (2013) Comparative diagnostic performance of 18F-FDG PET/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation. Eur Radiol 23(2):570–578. http://link.springer.com/10.1007/s00330-012-2600-5
Dhakal B, Vesole DH, Hari PN (2016) Allogeneic stem cell transplantation for multiple myeloma: is there a future? Bone Marrow Transplant 51(4):492–500. https://doi.org/10.1038/bmt.2015.325. Epub 2016 Jan 4
Dimopoulos M, Terpos E, Comenzo RL, Tosi P, Beksac M, Sezer O et al (2009) International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma. Leukemia 23(9):1545–1556. http://www.nature.com/doifinder/10.1038/leu.2009.89
Dongen JJM, Seriu T, Panzer-Grümayer ER, Biondi A, Pongers-Willemse MJ, Corral L, Stolz F, Schrappe M, Masera G, Kamps WA, Gadner H, Van Wering ER, Ludwig W-D, Basso G, MAC DB, Cazzaniga G, Hettinger K, Van der Does-van den Berg A, WCJ H, Riehm H, Bartram CR (1998) Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 352:1731–1738
Dores GM, Landgren O, KA MG, Curtis RE, Linet MS, Devesa SS (2009) Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992–2004. Br J Haematol 144(1):86–94. http://doi.wiley.com/10.1111/j.1365-2141.2008.07421.x
Drandi D, Kubiczkova-Besse L, Ferrero S, Dani N, Passera R, Mantoan B, Gambella M, Monitillo L, Saraci E, Ghione P, Genuardi E, Barbero D, Omedè P, Barberio D, Hajek R, Vitolo U, Palumbo A, Cortelazzo S, Boccadoro M, Inghirami G, Ladetto M (2015) Minimal residual disease detection by droplet digital PCR in multiple myeloma, mantle cell lymphoma, and follicular lymphoma: a comparison with real-time PCR. J Mol Diagn 17(6):652–660. https://doi.org/10.1016/j.jmoldx.2015.05.007. Epub 2015 Aug 28
Durie BGM, Harousseau J-L, Miguel JS, Bladé J, Barlogie B, Anderson K et al (2006) International uniform response criteria for multiple myeloma. Leukemia 20(9):1467–1473. http://www.ncbi.nlm.nih.gov/pubmed/16855634
Elliott BM, Peti S, Osman K, Scigliano E, Lee D, Isola L et al (2011) Combining FDG-PET/CT with laboratory data yields superior results for prediction of relapse in multiple myeloma. Eur J Haematol 86(4):289–298. http://doi.wiley.com/10.1111/j.1600-0609.2010.01575.x
Ferrero S et al (2011) Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms. Hematol Oncol 29(4):167–176
Ferrero S, Ladetto M, Drandi D, Cavallo F, Genuardi E, Urbano M et al (2015) Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics’ impact on survival. Leukemia 29(3):689–695. http://www.nature.com/doifinder/10.1038/leu.2014.219
Figueiredo A, Atkins H, Kekre N, Kew A, McCurdy A (2016) Allogeneic stem cell transplantation for multiple myeloma: a single center experience. Blood 128:5874
Flanders A, Stetler-Stevenson M, Landgren O (2013) Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity. Blood 122(6):1088–1089. http://www.bloodjournal.org/cgi/doi/10.1182/blood-2013-05-506170
Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, García-Sánchez O, Böttcher S, van der Velden VH, Pérez-Morán JJ, Vidriales MB, García-Sanz R, Jimenez C, González M, Martínez-López J, Corral-Mateos A, Grigore GE, Fluxá R, Pontes R, Caetano J, Sedek L, Del Cañizo MC, Bladé J, Lahuerta JJ, Aguilar C, Bárez A, García-Mateo A, Labrador J, Leoz P, Aguilera-Sanz C, San-Miguel J, Mateos MV, Durie B, van Dongen JJ, Orfao A (2017) Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia 31(10):2094–2103. https://doi.org/10.1038/leu.2017.29
Fraioli F, Punwani S (2014) Clinical and research applications of simultaneous positron emission tomography and MRI. Br J Radiol 87(1033):20130464. http://www.birpublications.org/doi/10.1259/bjr.20130464
García-Sanz R, Orfão A, González M, Tabernero MD, Bladé J, Moro MJ et al (1999) Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood 93(3):1032–1037. http://www.ncbi.nlm.nih.gov/pubmed/9920853
Giarin MM, Giaccone L, Sorasio R, Sfiligoi C, Amoroso B, Cavallo F et al (2009) Serum free light chain ratio, total kappa/lambda ratio, and immunofixation results are not prognostic factors after stem cell transplantation for newly diagnosed multiple myeloma. Clin Chem 55(8):1510–1516. http://www.clinchem.org/cgi/doi/10.1373/clinchem.2009.124370
Gribben JG, Freedman AS, Neuberg D, Roy DC, Blake KW, Woo SD, Grossbard ML, Rabinowe SN, Coral F, Freeman GJ et al (1991) Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 325(22):1525–1533
Harousseau J-L, Attal M, Avet-Loiseau H (2009) The role of complete response in multiple myeloma. Blood 114:3139–3146. https://doi.org/10.1182/blood-2009-03-201053
Hillengass J, Landgren O (2013) Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: imaging “early myeloma”. Leuk Lymphoma 54(7):1355–1363. http://www.tandfonline.com/doi/full/10.3109/10428194.2012.740559
Hillengass J, Bäuerle T, Bartl R, Andrulis M, McClanahan F, Laun FB et al (2011) Diffusion-weighted imaging for non-invasive and quantitative monitoring of bone marrow infiltration in patients with monoclonal plasma cell disease: a comparative study with histology. Br J Haematol 153(6):721–728. http://doi.wiley.com/10.1111/j.1365-2141.2011.08658.x
Kapoor P, Kumar SK, Dispenzieri A, Lacy MQ, Buadi F, Dingli D et al (2013) Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J Clin Oncol 31(36):4529–4535. http://ascopubs.org/doi/10.1200/JCO.2013.49.0086
Knulst AC, Adriaansen HJ, Hählen K, Stigter JC, van den Beemd MW, Hagemeijer A, van Dongen JJ, Hooijkaas H (1993) Early diagnosis of smoldering acute lymphoblastic leukemia using immunological marker analysis. Leukemia 7(4):532–536
Korthals M, Sehnke N, Kronenwett R et al (2012) The level of minimal residual disease in the bone marrow of patients with multiple myeloma before high-dose therapy and autologous blood stem cell transplantation is an independent predictive parameter. Biol Blood Marrow Transplant 18:423–431
Kotrova M et al (2017) Is next-generation sequencing the way to go for residual disease monitoring in acute lymphoblastic leukemia? Mol Diagn Ther 21:481–492. https://doi.org/10.1007/s40291-017-0277-9
Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S et al (2014) Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 28(5):1122–1128. http://www.nature.com/doifinder/10.1038/leu.2013.313
Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P et al (2016) International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17(8):e328–e346. http://www.ncbi.nlm.nih.gov/pubmed/27511158
Ladetto M, Donovan JW, Harig S, Trojan A, Poor C, Schlossnan R, Anderson KC, Gribben JG (2000) Real-time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma. Biol Blood Marrow Transplant 6(3):241–253
Ladetto M, Pagliano G, Ferrero S, Cavallo F, Drandi D, Santo L et al (2010) Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol 28(12):2077–2084. http://ascopubs.org/doi/10.1200/JCO.2009.23.7172
Ladetto M, Brüggemann M, Monitillo L, Ferrero S, Pepin F, Drandi D, Barbero D, Palumbo A, Passera R, Boccadoro M, Ritgen M, Gökbuget N, Zheng J, Carlton V, Trautmann H, Faham M, Pott C (2014) Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. Leukemia 28(6):1299–1307. https://doi.org/10.1038/leu.2013.375. Epub 2013 Dec 17
Ladetto M, Ferrero S, Drandi D, Festuccia M, Patriarca F, Mordini N, Cena S, Benedetto R, Guarona G, Ferrando F, Brunello L, Ghione P, Boccasavia V, Fanin R, Omedè P, Giaccone L, Palumbo A, Passera R, Boccadoro M, Bruno B (2015) Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma. Leukemia 30(5):1211–1214. https://doi.org/10.1038/leu.2015.269
Lahuerta JJ, Paiva B, Vidriales MB, Cordón L, Cedena MT, Puig N, Martinez-Lopez J, Rosiñol L, Gutierrez NC, Martín-Ramos ML, Oriol A, Teruel AI, Echeveste MA, de Paz R, de Arriba F, Hernandez MT, Palomera L, Martinez R, Martin A, Alegre A, De la Rubia J, Orfao A, Mateos MV, Blade J, San-Miguel JF, GEM (Grupo Español de Mieloma)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Group (2017) Depth of response in multiple myeloma: a pooled analysis of three PETHEMA/GEM clinical trials. J Clin Oncol 35(25):2900–2910. https://doi.org/10.1200/JCO.2016.69.2517
Lin P, Owens R, Tricot G, Wilson CS (2004) Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol 121(4):482–488. http://www.ncbi.nlm.nih.gov/pubmed/15080299
Martinelli G, Terragna C, Zamagni E et al (2000) Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol 18:2273–2281
Martinez-Lopez J, Lahuerta JJ, Pepin F, González M, Barrio S, Ayala R et al (2014) Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood 123(20):3073–3079. http://www.bloodjournal.org/cgi/doi/10.1182/blood-2014-01-550020
Martinez-Lopez J, Sanchez-Vega B, Barrio S, Cuenca I, Ruiz-Heredia Y, Alonso R, Rapado I, Marin C, Cedena M-T, Paiva B, Puig N, Mateos M-V, Ayala R, Hernández M-T, Jimenez C, Rosiñol L, Martínez R, Teruel A-I, Gutiérrez N, Martin-Ramos M-L, Oriol A, Bargay J, Bladé J, San-Miguel J, Garcia-Sanz R, Lahuerta J-J (2017) Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma. Leukemia 31(6):1446–1449. https://doi.org/10.1038/leu.2017.58
Martinez-Sanchez P, Montejano L, Sarasquete ME et al (2008) Evaluation of minimal residual disease in multiple myeloma patients by fl uorescent-polymerase chain reaction: the prognostic impact of achieving molecular response. Br J Haematol 142:766–774
Mateo Manzanera G, San Miguel Izquierdo JF, Orfao de Matos A (2005) Immunophenotyping of plasma cells in multiple myeloma. Methods Mol Med 113:5–24. http://www.ncbi.nlm.nih.gov/pubmed/15968091
Mateos M-V, San Miguel JF (2013) How should we treat newly diagnosed multiple myeloma patients? Hematol Am Soc Hematol Educ Progr 2013(1):488–495. http://www.asheducationbook.org/cgi/doi/10.1182/asheducation-2013.1.488
Mateos M-V, Oriol A, Martínez-López J, Teruel A-I, López de la Guía A, López J et al (2014) GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators? Blood 124(12):1887–1893. http://www.ncbi.nlm.nih.gov/pubmed/25102853
McCarthy PL, Hahn T (2013) Strategies for induction, autologous hematopoietic stem cell transplantation, consolidation, and maintenance for transplantation-eligible multiple myeloma patients. Hematol Am Soc Hematol Educ Progr 2013(1):496–503. http://www.asheducationbook.org/cgi/doi/10.1182/asheducation-2013.1.496
Moreau P, Robillard N, Jégo G, Pellat C, Le Gouill S, Thoumi S et al (2006) Lack of CD27 in myeloma delineates different presentation and outcome. Br J Haematol 132(2):168–170. http://www.ncbi.nlm.nih.gov/pubmed/16398651
Nowakowski GS, Witzig TE, Dingli D, Tracz MJ, Gertz MA, Lacy MQ et al (2005) Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood 106(7):2276–2279. http://www.ncbi.nlm.nih.gov/pubmed/15961515
Ocio EM, Richardson PG, Rajkumar SV, Palumbo A, Mateos MV, Orlowski R et al (2014) New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the international myeloma working group (IMWG). Leukemia 28(3):525–542. http://www.nature.com/doifinder/10.1038/leu.2013.350
Paiva B, Vidriales M-B, Cerveró J, Mateo G, Pérez JJ, Montalbán MA et al (2008) Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 112(10):4017–4023. http://www.bloodjournal.org/cgi/doi/10.1182/blood-2008-05-159624
Paiva B, Almeida J, Pérez-Andrés M, Mateo G, López A, Rasillo A et al (2010) Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders. Cytometry B Clin Cytom 78(4):239–252. http://doi.wiley.com/10.1002/cyto.b.20512
Paiva B, Martinez-Lopez J, Vidriales M-B, Mateos M-V, Montalban M-A, Fernandez-Redondo E et al (2011) Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol 29(12):1627–1633. http://ascopubs.org/doi/10.1200/JCO.2010.33.1967
Paiva B, Gutierrez NC, Rosinol L, for the GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Groups et al (2012) High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood 119:687–691
Paiva B, Puig N, García-Sanz R, San Miguel JF, Grupo Español de Mieloma (GEM)/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (PETHEMA) cooperative study groups (2015) Is this the time to introduce minimal residual disease in multiple myeloma clinical practice? Clin Cancer Res 21(9):2001–2008. http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0432.CCR-14-2841
Pawlyn C, Fowkes L, Otero S, Jones JR, Boyd KD, Davies FE et al (2016) Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma? Leukemia 30(6):1446–1448. http://www.nature.com/doifinder/10.1038/leu.2015.338
Pedreira CE, Costa ES, Lecrevisse Q, van Dongen JJM, Orfao A, EuroFlow Consortium (2013) Overview of clinical flow cytometry data analysis: recent advances and future challenges. Trends Biotechnol 31(7):415–425. http://linkinghub.elsevier.com/retrieve/pii/S0167779913000942
Pérez-Andrés M, Almeida J, Martín-Ayuso M, Moro MJ, Martín-Nuñez G, Galende J et al (2005) Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment. Leukemia 19(3):449–455. http://www.ncbi.nlm.nih.gov/pubmed/15674420
Puig N, Sarasquete ME, Balanzategui A, Martínez J, Paiva B, García H et al (2014) Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry. Leukemia 28(2):391–397. http://www.nature.com/doifinder/10.1038/leu.2013.217
Putkonen M, Kairisto V, Juvonen V et al (2010) Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma. Eur J Haematol 85:416–423
Rajkumar SV, Harousseau J-L, Durie B, Anderson KC, Dimopoulos M, Kyle R et al (2011) Consensus recommendations for the uniform reporting of clinical trials: report of the international myeloma workshop consensus panel 1. Blood 117(18):4691–4695. http://www.bloodjournal.org/cgi/doi/10.1182/blood-2010-10-299487
Rawstron AC, Barrans SL, Blythe D, English A, Richards SJ, Fenton JA et al (2001) In multiple myeloma, only a single stage of neoplastic plasma cell differentiation can be identified by VLA-5 and CD45 expression. Br J Haematol 113(3):794–802. http://www.ncbi.nlm.nih.gov/pubmed/11380472
Rawstron AC, Davies FE, DasGupta R, Ashcroft AJ, Patmore R, Drayson MT et al (2002) Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood 100(9):3095–3100. http://www.ncbi.nlm.nih.gov/pubmed/12384404
Rawstron AC, Child JA, de Tute RM, Davies FE, Gregory WM, Bell SE et al (2013) Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council myeloma IX study. J Clin Oncol 31(20):2540–2547. http://ascopubs.org/doi/10.1200/JCO.2012.46.2119
Robillard N, Pellat-Deceunynck C, Bataille R (2005) Phenotypic characterization of the human myeloma cell growth fraction. Blood 105(12):4845–4848. http://www.ncbi.nlm.nih.gov/pubmed/15741217
San Miguel JF, Almeida J, Mateo G, Bladé J, López-Berges C, Caballero D et al (2002) Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome. Blood 99(5):1853–1856. http://www.ncbi.nlm.nih.gov/pubmed/11861305
San Miguel JF, Gutiérrez NC, Mateo G, Orfao A (2006) Conventional diagnostics in multiple myeloma. Eur J Cancer 42(11):1510–1519. http://www.ncbi.nlm.nih.gov/pubmed/16762540
Sarasquete ME, Garcia-Sanz R, Gonzalez D, Martinez J, Mateo G, Martinez P, Ribera JM, Hernandez JM, Lahuerta JJ, Orfao A, Gonzalez M, San Miguel JF (2005) Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica 90:1365–1372
Sheth N, Yeung J, Chang H (2009) p53 nuclear accumulation is associated with extramedullary progression of multiple myeloma. Leuk Res 33(10):1357–1360. http://linkinghub.elsevier.com/retrieve/pii/S0145212609000174
Short KD, Rajkumar SV, Larson D, Buadi F, Hayman S, Dispenzieri A et al (2011) Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia 25(6):906–908. http://www.nature.com/doifinder/10.1038/leu.2011.29
Shortt CP, Gleeson TG, Breen KA, McHugh J, O’Connell MJ, O’Gorman PJ et al (2009) Whole-body MRI versus PET in assessment of multiple myeloma disease activity. AJR Am J Roentgenol 192(4):980–986. http://www.ajronline.org/doi/10.2214/AJR.08.1633
Tarella C, Corradini P, Astolfi M, Bondesan P, Caracciolo D, Cherasco C, Ladetto M, Giaretta F, Ricca I, Vitolo U, Pileri A, Ferrero D (1999) Negative immunomagnetic ex vivo purging combined with high-dose chemotherapy with peripheral blood progenitor cell autograft in follicular lymphoma patients: evidence for long-term clinical and molecular remissions. Leukemia 13(9):1456
Thiago LS, Perez-Andres M, Balanzategui A, Sarasquete ME, Paiva B, Jara-Acevedo M et al (2014) Circulating clonotypic B cells in multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica 99(1):155–162. http://www.haematologica.org/cgi/doi/10.3324/haematol.2013.092817
Usmani SZ, Heuck C, Mitchell A, Szymonifka J, Nair B, Hoering A et al (2012) Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica 97(11):1761–1767. http://www.haematologica.org/cgi/doi/10.3324/haematol.2012.065698
Usmani SZ, Mitchell A, Waheed S, Crowley J, Hoering A, Petty N et al (2013) Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood 121(10):1819–1823. http://www.bloodjournal.org/cgi/doi/10.1182/blood-2012-08-451690
van der Velden VH, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen JJ (2003) Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 17(6):1013–1034
van der Velden VH, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER, Flohr T, Sutton R, Cave H, Madsen HO, Cayuela JM, Trka J, Eckert C, Foroni L, Zur Stadt U, Beldjord K, Raff T, van der Schoot CE, van Dongen JJ, European Study Group on MRD detection in ALL (ESG-MRD-ALL) (2007) Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 21(4):604–611. Epub 2007 Feb 8
van Lammeren-Venema D, Regelink JC, Riphagen II, Zweegman S, Hoekstra OS, Zijlstra JM (2012) 18F-fluoro-deoxyglucose positron emission tomography in assessment of myeloma-related bone disease: a systematic review. Cancer 118(8):1971–1981. http://doi.wiley.com/10.1002/cncr.26467
Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M (2010) Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol Off J Eur Soc Med Oncol 21(2):325–330. https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdp329
Voena C, Ladetto M, Astolfi M, Provan D, Gribben JG, Boccadoro M, Pileri A, Corradini P (1997) A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors. Leukemia 11(10):1793–1798
Walker RC, Brown TL, Jones-Jackson LB, De Blanche L, Bartel T (2012) Imaging of multiple myeloma and related plasma cell dyscrasias. J Nucl Med 53(7):1091–1101. http://jnm.snmjournals.org/cgi/doi/10.2967/jnumed.111.098830
Wren D, Walker B, Bruggemann M, Catherwood M, Pott C, Stamatopoulos K, Langerak A, Gonzalez D (2014) Translocations and clonality detection in lymphoproliferative disorders by capture-based next-generation sequencing. A pilot study by the euroclonality-ngs consortium. Blood 124:5169
Zamagni E, Patriarca F, Nanni C, Zannetti B, Englaro E, Pezzi A et al (2011) Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood 118(23):5989–5995. http://www.bloodjournal.org/cgi/doi/10.1182/blood-2011-06-361386
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Puig, N., Palladino, C., Paiva, B., Ladetto, M. (2018). Minimal Residual Disease in Multiple Myeloma. In: Dimopoulos, M., Facon, T., Terpos, E. (eds) Multiple Myeloma and Other Plasma Cell Neoplasms. Hematologic Malignancies. Springer, Cham. https://doi.org/10.1007/978-3-319-25586-6_6
Download citation
DOI: https://doi.org/10.1007/978-3-319-25586-6_6
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-25584-2
Online ISBN: 978-3-319-25586-6
eBook Packages: MedicineMedicine (R0)